Scarica l'app Stockscreener
1.42
0.70%
-0.01
Dopo l'orario di chiusura:
1.42
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.43
Aprire:
$1.47
Volume 24 ore:
293.86K
Relative Volume:
0.82
Capitalizzazione di mercato:
$93.01M
Reddito:
-
Utile/perdita netta:
$-30.04M
Rapporto P/E:
-0.8402
EPS:
-1.69
Flusso di cassa netto:
$-27.38M
1 W Prestazione:
+0.71%
1M Prestazione:
-9.55%
6M Prestazione:
-29.00%
1 anno Prestazione:
-1.39%
Intervallo 1D:
$1.38
$1.47
Intervallo di 1 settimana:
$1.38
$1.65
Portata 52W:
$1.08
$3.79
Regulus Therapeutics Inc Stock (RGLS) Company Profile
Nome
Regulus Therapeutics Inc
Settore
Industria
Telefono
858-202-6300
Indirizzo
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Confronta RGLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| RGLS | 1.42 | 93.01M | 0 | -30.04M | -27.38M | -1.69 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-02 | Iniziato | Oppenheimer | Outperform |
| 2024-03-18 | Iniziato | Leerink Partners | Outperform |
| 2018-03-28 | Iniziato | B. Riley FBR, Inc. | Neutral |
| 2018-01-05 | Iniziato | Leerink Partners | Outperform |
| 2017-06-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-03-06 | Reiterato | Wedbush | Outperform |
| 2017-01-30 | Downgrade | Needham | Buy → Hold |
| 2017-01-30 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2016-12-07 | Reiterato | Chardan Capital Markets | Buy |
| 2016-11-02 | Reiterato | Needham | Buy |
| 2016-07-25 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | FBR Capital | Outperform |
| 2016-06-28 | Reiterato | Needham | Buy |
| 2016-06-07 | Reiterato | Chardan Capital Markets | Buy |
| 2016-04-13 | Iniziato | Chardan Capital Markets | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-06-09 | Iniziato | Guggenheim | Buy |
| 2015-04-21 | Ripresa | FBR Capital | Outperform |
| 2014-11-24 | Iniziato | Deutsche Bank | Buy |
| 2014-08-07 | Reiterato | FBR Capital | Outperform |
| 2013-08-14 | Reiterato | Needham | Buy |
Mostra tutto
Regulus Therapeutics Inc Borsa (RGLS) Ultime notizie
Annovis Bio (NYSE:ANVS) versus Regulus Therapeutics (NASDAQ:RGLS) Head-To-Head Contrast - Defense World
Biotechnology Value Fund L.P. Increases Stake in Regulus Therape - GuruFocus.com
What is HC Wainwright’s Estimate for RGLS FY2024 Earnings? - Defense World
FY2024 Earnings Forecast for RGLS Issued By HC Wainwright - MarketBeat
Creative Planning Makes New Investment in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from HC Wainwright - MarketBeat
Regulus: Q3 Earnings Snapshot - San Francisco Chronicle
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates - PR Newswire
Regulus Therapeutics (RGLS) Stock Price, News & Analysis - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Regulus Therapeuti - GuruFocus.com
HC Wainwright Reiterates Buy Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts - MarketBeat
Regulus Therapeutics secures exclusive license for kidney disease treatment - Investing.com India
Regulus Therapeutics secures exclusive license for kidney disease treatment By Investing.com - Investing.com South Africa
Regulus Therapeutics Inc. Enters into Patent & Technology License Agreement with the Board of Regents of the University of Texas System - Marketscreener.com
Financial Survey: Regulus Therapeutics (NASDAQ:RGLS) & Ironwood Pharmaceuticals (NASDAQ:IRWD) - Defense World
Renaissance Technologies LLC Has $211,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
HC Wainwright Reaffirms "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat
RGLSRegulus Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PR Newswire
Analysts Set Regulus Therapeutics Inc. (NASDAQ:RGLS) PT at $10.80 - MarketBeat
Company’s Banking Stock: Dissecting a -7.22% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Regulus Therapeutics Inc [RGLS] stock for 7,280 USD was acquired by Collier Kathryn J - Knox Daily
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Sold by CVI Holdings LLC - MarketBeat
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth - Simply Wall St
ProMIS Neurosciences (NASDAQ:PMN) versus Regulus Therapeutics (NASDAQ:RGLS) Critical Contrast - Defense World
Investing in Regulus Therapeutics Inc (RGLS) Is Getting More Attractive - Knox Daily
Victory Capital Management Inc. Has $645,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Stock Rating Upgraded by StockNews.com - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Upgraded to "Sell" by StockNews.com - MarketBeat
Oppenheimer’s latest rating for RGLS stock - Knox Daily
RGLS stock rated an Outperform by Oppenheimer - Knox Daily
Gaining Ground: Regulus Therapeutics Inc (RGLS) Closes Lower at 1.46, Down -6.41 - The Dwinnex
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Regulus Therapeutics (NASDAQ:RGLS) Raised to Sell at StockNews.com - MarketBeat
Regulus Therapeutics Inc [RGLS] Director makes an insider purchase of 4,000 shares worth 7280.0. - Knox Daily
Regulus Therapeutics Inc (RGLS) rating initates by Oppenheimer - Knox Daily
How does Regulus Therapeutics Inc (RGLS) change from a tortoise to a hare? - SETE News
Regulus Therapeutics Inc (RGLS) stock analysis: A comprehensive overview - US Post News
Regulus Therapeutics Inc (RGLS)’s stock chart: A technical perspective - US Post News
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - StockTitan
The Attractiveness of Investing In Regulus Therapeutics Inc (RGLS) is Growing - Knox Daily
Market Recap: Regulus Therapeutics Inc (RGLS)’s Positive Momentum, Closing at 1.59 - The Dwinnex
A Guide To The Risks Of Investing In Regulus Therapeutics Inc (RGLS) - Knox Daily
Vanguard Group Inc. Has $2.13 Million Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
Regulus Therapeutics Reports Second Quarter 2024 Financial Resul - GuruFocus.com
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - Longview News-Journal
Oppenheimer Reiterates “Outperform” Rating for Regulus Therapeutics (NASDAQ:RGLS) - Defense World
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Oppenheimer Reiterates Outperform Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat
Analyzing Regulus Therapeutics Inc (RGLS) After Recent Trading Activity - Knox Daily
Regulus Therapeutics Inc Azioni (RGLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):